|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Panbela Therapeutics, Inc. (PBLA) |
|
|
$6.87 0.00 (0.00%) as of 4:30 Fri 1/19
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
9,650,000 |
| Market
Cap: |
66.30(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4338 - $7.13 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Panbela Therapeutics is a clinical stage biopharmaceutical company developing therapeutics for the treatment of patients with cancer. Co.'s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition, a metabolic pathway of critical importance in multiple tumor types.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
406,888 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
5 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
0 |
0 |
72,874 |
72,874 |
| Total Sell Value |
$0 |
$0 |
$51,741 |
$51,741 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mathiesen Jeffrey S |
Director |
• • – |
2018-02-20 |
4 |
B |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
2.31 |
- |
|
| Kellen Scott |
Chief Financial Officer |
• • – |
2018-02-20 |
4 |
B |
$0.00 |
$0 |
D/D |
1,000 |
4,500 |
2.66 |
- |
|
| Cullen Michael T. |
Executive Chairman |
• • • |
2018-02-20 |
4 |
B |
$0.00 |
$0 |
I/I |
5,000 |
194,576 |
2.56 |
- |
|
| Gilbertson Ryan Randall |
10% Owner |
• • • |
2017-12-13 |
4 |
D |
$13.03 |
$150,001 |
D/D |
(11,512) |
555,538 |
|
- |
|
| Gilbertson Ryan Randall |
10% Owner |
• • • |
2017-12-13 |
4 |
OE |
$1.88 |
$150,000 |
D/D |
80,000 |
567,050 |
|
- |
|
| Gilbertson Ryan Randall |
10% Owner |
• • • |
2017-03-27 |
4 |
A |
$0.75 |
$210,000 |
I/I |
280,000 |
280,000 |
|
- |
|
| Gilbertson Ryan Randall |
10% Owner |
• • • |
2017-03-27 |
4 |
A |
$0.75 |
$525,000 |
D/D |
700,000 |
4,870,508 |
|
- |
|
| Cullen Michael T. |
Executive Chairman |
• • • |
2016-12-21 |
5 |
GD |
$0.00 |
$0 |
D/D |
45,000 |
1,575,000 |
|
- |
|
| Schemel Donald Robert |
Director |
• • • |
2016-11-14 |
4 |
S |
$1.43 |
$10,010 |
I/I |
(7,000) |
2,826,548 |
|
- |
|
| Gagnon Suzanne |
Director |
• • – |
2016-06-24 |
4 |
B |
$0.00 |
$0 |
D/D |
30,000 |
430,000 |
2.31 |
- |
|
| Kaysen David B |
President and CEO |
• • – |
2016-06-24 |
4 |
B |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
2.73 |
- |
|
| Kellen Scott |
Chief Financial Officer |
• • – |
2016-06-24 |
4 |
B |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
2.66 |
- |
|
| Cullen Michael T. |
Executive Chairman |
• • – |
2016-06-24 |
4 |
B |
$0.00 |
$0 |
I/I |
50,000 |
1,895,764 |
2.58 |
- |
|
| Schaffer Paul W. |
Director |
• • – |
2016-06-24 |
4 |
B |
$0.00 |
$0 |
I/I |
100,000 |
189,092 |
2.02 |
- |
|
| Sargent Robert John |
Former Director |
– – – |
2015-09-08 |
4 |
S |
$0.00 |
$0 |
I/I |
(216,705) |
74,825 |
|
- |
|
| Fuhrman David Michael |
Former Officer/Director |
– – – |
2015-09-08 |
4 |
S |
$0.00 |
$0 |
D/D |
(300,561) |
158,175 |
|
- |
|
| Gagnon Suzanne |
Director |
– • – |
2015-09-04 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
10,000 |
|
- |
|
| Neenan Thomas X. |
Chief Scientific OfficerOffice |
• • – |
2015-09-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
400,000 |
|
- |
|
| Gilbertson Ryan Randall |
10% Owner |
– – • |
2015-09-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,170,508 |
|
- |
|
| Schemel Donald Robert |
Director |
– • – |
2015-09-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,833,548 |
|
- |
|
| Schemel Donald Robert |
Director |
– • – |
2015-09-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
894,288 |
|
- |
|
| Gagnon Suzanne |
Chief Medical OfficerOfficer |
• • – |
2015-09-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
400,000 |
|
- |
|
| Cullen Michael T. |
Director |
– • – |
2015-09-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,845,764 |
|
- |
|
| Cullen Michael T. |
Director |
– • – |
2015-09-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,620,000 |
|
- |
|
| Schaffer Paul W. |
Director |
– • – |
2015-09-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
89,092 |
|
- |
|
78 Records found
|
|
Page 3 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
